Search bioRxiv⌕ Search

Biology subjects

Mengesha, B.

Publications and source records attributed to Mengesha, B..

2 recordsLinked to original sources

Deep learning-based identification and quantification of rare circulating hybrid cells in orthotopic pancreatic cancer models

SignificanceRare-cell identification in fluorescence microscopy remains challenging because targets are sparse and background varies between specimens. Combining specimen-specific fluorescence enrichment with image classification may enable efficient and more specific automated detection of rare cells. AimWe developed a two-stage framework to identify and quantify candidate rare circulating hybrid neoplastic cells (CHCs, ECAD+/CD45+) in peripheral blood mononuclear cell (PBMC) preparations from tumor-bearing and tumor-naive mice. ApproachPBMCs from 28 mice were imaged by multichannel fluorescence microscopy. Matched unstained samples established animal-specific ECAD and CD45 background distributions for candidate cell enrichment. Blinded multi-annotator consensus labels were used to train a convolutional neural network (CNN) from DAPI, ECAD, and CD45 image crops. Generalization was evaluated by leave-one-animal-out validation across 10 random initializations. Final classification used a 10-model ensemble, and rare-cell burden was compared between groups using negative-binomial regression with total segmented-cell count as an exposure. ResultsOf the 1,065,512 segmented cells, enrichment retained 10,176 candidates (0.96%), reducing the search space by >99%. Four of five evaluable tumor-bearing animals showed reproducible held-out discrimination, with median quantified area under the receiver operator characteristic curve (AUROCs) of 0.918-0.951; one animal was a reproducible outlier (median AUROC, 0.338). Ensemble deployment identified 157.94 positive-consensus cells per 50,000 segmented cells in tumor-bearing animals versus 49.55 in controls. The estimated rare-cell rate was 3.15-fold higher in tumor-bearing animals (95% CI, 0.91-10.99; two-sided p=0.071; prespecified one-sided p=0.036). ConclusionsSpecimen-specific fluorescence enrichment combined with supervised image classification reduced the cellular search space and enabled automated quantification of a rare CHC (ECAD+/CD45+) phenotypes. Cross-animal validation also identified specimen-specific generalization failure, highlighting the importance of biological-specimen-level validation.

cancer biology↗

BBB-Permeable Near-Infrared Oxazine Fluorophores for White Matter Tract Imaging

Preserving critical functional tissue remains a major challenge in fluorescence-guided surgery (FGS), particularly in neurosurgery where injury to white matter tracts can lead to lasting neurological deficits. Probes for preventing iatrogenic injury of the peripheral nervous system have highlighted the potential of real-time intraoperative guidance for nerve-sparing surgery, supporting improved preservation of critical functional tissue, but analogous tools for the central nervous system remain limited. While there are some awake mapping and MRI based techniques that try to minimize the resection of white matter tracts (WMTs), they do not provide surgeons with real-time visualization. To address this gap, we rationally translated a peripheral nerve targeted oxazine fluorophore platform into a library of novel oxazine dyes that can penetrate the blood-brain barrier (BBB), exhibit specificity for white matter tissue and maintain spectral compatibility with clinically relevant imaging systems. Guided by our fluorophore medicinal chemistry platform, this work includes library design, photophysical property characterization, in vivo WMTs specificity screening, and in vivo imaging window assessment of the lead candidates to evaluate neurosurgical workflow compatibility. The lead candidate identified from this library demonstrated strong in vivo WMTs-specific fluorescence intensity, contrast and imaging window compatible with neurosurgical workflows, establishing BBB-permeable oxazine fluorophores as a promising scaffold for future structure-sparing neurosurgical FGS.

bioengineering↗